Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CDC25B | P30305 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | APAF1 | O14727 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | TDP2 | O95551 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | S100A4 | P26447 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 1/20 | 0.50 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthraquinone SCHEMBL28270692 | 1.00 | MEN1 (0.60) | MEN1KMT2ACDC25BRAB9APOLB | |
| SCHEMBL28245677 | 0.98 | MEN1 (0.57) | MEN1KMT2ACDC25BRAB9APOLB | |
| SCHEMBL28272504 | 0.84 | MEN1 (0.38) | MEN1KMT2ACDC25BRAB9APOLB | |
| Anthrone SCHEMBL27433230 | 0.83 | MAOA (0.69) | MEN1KMT2ACDC25BRAB9ASMN1; SMN2 | |
| Phthalimide SCHEMBL27471434 | 0.81 | GSK3B (0.68) | MEN1KMT2ACDC25BPOLBSMN1; SMN2 | |
| Naphthoquinone SCHEMBL27950218 | 0.81 | CDC25B (0.64) | MEN1KMT2ACDC25BRAB9APOLB | |
| Anthraquinone SCHEMBL2478622 | 0.78 | MEN1 (0.86) | MEN1KMT2ACDC25BRAB9APOLB | |
| Anthraquinone SCHEMBL1445042 | 0.78 | MEN1 (0.86) | MEN1KMT2ACDC25BRAB9APOLB | |
| Anthraquinone SCHEMBL29358690 | 0.78 | MEN1 (1.00) | MEN1KMT2ACDC25BRAB9APOLB | |
| Anthraquinone SCHEMBL14943 | 0.78 | MEN1 (1.00) | MEN1KMT2ACDC25BRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101712648-B | Synthesis method of azepine anthraquinone | NANJING UNIVERSITY OF TECHNOLOGY | 2011-11-09 | — | — | CN | claimed |
| CN-101712648-A | Synthesis method of azepine anthraquinone | NANJING UNIVERSITY OF TECHNOLOGY | 2010-05-26 | — | — | CN | claimed |
| US-20240041849-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2024-02-08 | — | — | US | disclosed |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220125774-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3829560-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | Musc Foundation for Research Development (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020028222-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2020-02-06 | — | — | WO | disclosed |
| CN-105637038-B | Novel compound and composition containing the same | 株式会社艾迪科 | 2019-10-25 | — | — | CN | disclosed |
| CN-104334684-B | Latent additive and composition containing the same | 株式会社艾迪科 | 2019-08-27 | — | — | CN | disclosed |
| CN-109922793-A | Poorly water soluble dietary supplements and methods of solubilizing pharmaceutically active agents | 雅典娜股份公司 | 2019-06-21 | — | — | CN | disclosed |
| CN-108699183-A | Composition and new compound | 株式会社艾迪科 | 2018-10-23 | — | — | CN | disclosed |
| CN-104334684-A | Latent additive and composition containing the same | ADEKA CORP | 2015-02-04 | — | — | CN | disclosed |
| CN-101712648-B | Synthesis method of azepine anthraquinone | NANJING UNIVERSITY OF TECHNOLOGY | 2011-11-09 | — | — | CN | disclosed |
| CN-101712648-B | Synthesis method of azepine anthraquinone | NANJING UNIVERSITY OF TECHNOLOGY | 2011-11-09 | — | — | CN | disclosed |
| CN-101712648-B | Synthesis method of azepine anthraquinone | NANJING UNIVERSITY OF TECHNOLOGY | 2011-11-09 | — | — | CN | disclosed |
| CN-101712648-A | Synthesis method of azepine anthraquinone | NANJING UNIVERSITY OF TECHNOLOGY | 2010-05-26 | — | — | CN | disclosed |
| CN-101712648-A | Synthesis method of azepine anthraquinone | NANJING UNIVERSITY OF TECHNOLOGY | 2010-05-26 | — | — | CN | disclosed |
| CN-101712648-A | Synthesis method of azepine anthraquinone | NANJING UNIVERSITY OF TECHNOLOGY | 2010-05-26 | — | — | CN | disclosed |
| CN-1139575-C | Process for preparing quinoline-5, 8-diones | L���������鹫˾ | 2004-02-25 | — | — | CN | disclosed |
| CN-1370149-A | Process for preparing quinoline-5, 8-diones | LAFON LABOR (FR) | 2002-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041849-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MT-ND2, MT-ND1, NLN | MEN1 917/4885KMT2A 869/4885CDC25B 3047/4885 |
| US-11771685-B2 | Compounds for the treatment of neurological or mitochondrial diseases | MT-ND2, MT-ND1, NLN | MEN1 917/4885KMT2A 869/4885CDC25B 3047/4885 |
| US-20220125774-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | MT-ND2, MT-ND1, NLN | MEN1 917/4885KMT2A 869/4885CDC25B 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.